Internal restructuring
Location of affected unit(s)
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.20 - Manufacture of pharmaceutical preparations

248 jobs
Number of planned job losses
Job loss
22 jobs
Number of planned job creations
Job creation
Announcement Date
20 March 2018
Employment effect (start)
1 June 2018
Foreseen end date
31 December 2018


In the framework of a global restructuring announced in December 2017 that will lead to cut 14,000 jobs worldwide, the Israelian group has announced a reorganisation of its French activities that will lead to cut 248 positions (on a total of 578) in its sales department and at its headquarter at Paris-La-Défense. The group will launch a voluntary departure plan and, will implement forced dismissals to complete the job cuts. On the total of 248 job cuts, 61 will result from the cancelation of vacant positions and 60 will consist of internal redemployment. The group will also hire 22 employees related to digitalisation. The group justifies this plan with drugs pricing, high costs due to regulatory and environmental requirements, and a delay in the expected penetration of Teva generic medicines in the country.


  • 20 March 2018: Le Monde


Eurofound (2018), Teva, Internal restructuring in France, factsheet number 93695, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/93695.